Improving immune response in lung cancer by targeting low oxygen levels in tumors
Official title: Targeting mitochondrial oxygen demand to overcome hypoxic immune privilege of NSCLC tumors
Funded at Ohio State University · NIH-10808602 · Data updated 2026-11-12
This study is looking at how low oxygen levels in lung cancer tumors can make it harder for the immune system to fight the cancer, and it aims to find new ways to boost the immune response to improve treatment options for patients with non-small cell lung cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $183,398 |
| NIH project number | 1K22CA282363-01A1 |
| Project ID | NIH-10808602 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are experiencing treatment resistance.
✕Less likely to help
Patients with other types of lung cancer or those who are not currently undergoing treatment for NSCLC may not benefit from this research.
What this research studies
This research investigates how low oxygen levels in non-small cell lung cancer (NSCLC) tumors affect the immune system's ability to fight cancer. It focuses on understanding the mechanisms behind treatment resistance and aims to develop new therapies that can enhance the effectiveness of existing immunotherapies. By studying the behavior of immune cells in the hypoxic tumor environment, the research seeks to identify ways to improve immune cell function and increase their infiltration into tumors. Patients may benefit from novel treatment strategies that could lead to better outcomes in managing NSCLC.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with non-small cell lung cancer, potentially increasing survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in targeting tumor hypoxia to enhance immune responses, suggesting that this approach could be effective in NSCLC as well.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Benej, Martin — Ohio State University
- Study coordinator: Benej, Martin
Related research
Other NIH-funded projects on the same topics.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
-
Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer
This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.
-
Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype
A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.
-
Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging
A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.
-
ATM kinase as a target to help NSCLC with brain metastases respond to treatment
A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.
-
Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies
A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.